X

Articles

Judge Strikes Down HRSA 340B Patient Definition

A South Carolina federal judge stuck down the HRSA definition of "patient" in the 340B program, a federal program designed to provide discounts on prescription drugs. Chief Judge R. Bryan Harwell, in the case of Genesis Health Care v. Becerra, ruled that the 340B statute does not require a healthcare service to be initiated before a prescription filled with a 340B drug can qualify under the program.

Judge Harwell's decision overruled a statement made by the Health Resources and Services Administration (HRSA) in a 2019 audit letter to Genesis Health Care, a federally qualified health center (FQHC). The HRSA letter stated that, in order for an individual to be considered a 340B patient, Genesis had to initiate the healthcare service leading to the prescription, regardless of whether the patient had any unrelated billable FQHC encounter.

Judge Harwell criticized HRSA's interpretation of the term "patient," calling it unconvincing, and asserted that the court is not legally bound to defer to HRSA's viewpoint on the matter. He emphasized that the healthcare industry has evolved significantly since the 340B statute's inception in 1992. Although he acknowledged the challenges HRSA faces in adapting to these changes, he argued that HRSA's attempt to limit covered entities' ability to increase their profit margin by altering the definition of "patient" exceeds its authority. He stated that any desire to amend the 340B program should come from Congress rather than HRSA.

However, Judge Harwell did not grant Genesis' request to declare that HRSA lacks broad rulemaking authority regarding the diversion of 340B drugs to ineligible patients. He recognized HRSA's authority to interpret the term "patient" to administer the 340B program's dispute resolution process but stressed that HRSA's interpretation must align with the statute's plain language and Congress's intent. In this case, the judge found HRSA's interpretation to be inconsistent with both.

 

 

The 340B Drug Pricing Program is managed by the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). For more information visit: www.hrsa.gov/opa This material is provided for general informational purposes of 340B Drug Prices only and is not an endorsement of any prescription product referenced herein. For information as to the clinical use or efficacy of a referenced product, please contact the manufacturer. 340B Price Guide makes no representations and provides no warranties as to the effectiveness or suitability for use of any prescription product referenced herein. Any referenced cost is provided as an estimate only and the actual cost is subject to change at any time and without notice. 340B Price Guide does not guarantee that the cost represented herein will be the actual and pharmacy shall at all times collect amounts due as indicated at the time of adjudication and shall be reimbursed per the terms of its agreement.'